NONE of these experts report that the OS data is confounded do they?? NWBO buried in a long SEC filing. So anybody that sees the TLD doesn't know that most of the patients were given multiple DCVax-L doses.
That is confounding and is results in favoring DCVax-L in the trial buy double dosing many of the patients likely inflating the survival. It is poor clinical trial design and is not a "well-controlled" clinical trial required for approval. FDA will know it and it should cause FUD.
Market Data 
Markets 
AI
